S. Guillaume

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

David Cameron, Richard Bell, Mitch Dowsett, 2007, The Lancet.

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Sung-Bae Kim, C. Sotiriou, L. Pusztai, 2021, Clinical Cancer Research.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

R. Gelber, J. Baselga, M. Ignatiadis, 2018, Cancer.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

R. Gelber, M. Piccart, G. Viale, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial

M. Procter, E. de Azambuja, N. Pondé, 2022, Ecancermedicalscience.

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

S. Loibl, M. Piccart-Gebhart, M. Procter, 2023, ESMO open.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

Sung-Bae Kim, C. Sotiriou, J. Huober, 2022, Journal for ImmunoTherapy of Cancer.

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos

R. Gelber, M. Piccart, G. Viale, 2020 .

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

E. Winer, R. Gelber, G. Viale, 2021 .

Abstract PS7-21: Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial

M. Procter, N. Pondé, E. Clark, 2021 .